Renjie Yang

1.0k total citations · 1 hit paper
50 papers, 694 citations indexed

About

Renjie Yang is a scholar working on Hepatology, Surgery and Molecular Biology. According to data from OpenAlex, Renjie Yang has authored 50 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hepatology, 19 papers in Surgery and 11 papers in Molecular Biology. Recurrent topics in Renjie Yang's work include Hepatocellular Carcinoma Treatment and Prognosis (27 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Cancer Mechanisms and Therapy (9 papers). Renjie Yang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (27 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Cancer Mechanisms and Therapy (9 papers). Renjie Yang collaborates with scholars based in China, Ethiopia and United States. Renjie Yang's co-authors include Xu Zhu, Guang Cao, Hui Chen, Baocai Xing, Sheng Han, Chenyu Jiao, Xiaodong Wang, Rui Peng, Xiaodong Wang and Quan Bao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Renjie Yang

46 papers receiving 687 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

2022 101 citations Xu Zhu, Guang Cao et al. Radiology profile →

Peers

Countries citing papers authored by Renjie Yang

Since Specialization

Citations

This map shows the geographic impact of Renjie Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renjie Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renjie Yang more than expected).

Fields of papers citing papers by Renjie Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renjie Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renjie Yang. The network helps show where Renjie Yang may publish in the future.

Co-authorship network of co-authors of Renjie Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Renjie Yang. A scholar is included among the top collaborators of Renjie Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renjie Yang. Renjie Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessing the quality of myopia prevention videos on Chinese short video platforms: a cross-sectional content analysis by source 2025 ·BMJ Open ·(unknown), Rong‐Bin Liang, (unknown), (unknown), Renjie Yang, Tao Li, Xiaodong Zhou	1
2	Stenting versus medical treatment alone for symptomatic intracranial artery stenosis: a preplanned pooled individual patient data analysis 2024 ·Journal of NeuroInterventional Surgery ·Tao Wang, Jichang Luo, (unknown), Eyad Almallouhi, Peng Gao, (unknown), Xiao Zhang, Jie Wang, Taoyuan Lu, Yifan Yang, Renjie Yang, (unknown), (unknown), Colin P. Derdeyn, Liqun Jiao	0
3	Drug-eluting stents versus bare-metal stents for intracranial atherosclerotic stenosis: a systematic review and meta-analysis 2024 ·BMJ Open ·(unknown), Jichang Luo, Wenlong Xu, Jie Wang, Renjie Yang, Bin Yang, Yan Ma, Tao Wang, Liqun Jiao	1
4	Stenting for symptomatic intracranial arterial stenosis with different qualifying arteries: a preplanned pooled individual patient data analysis 2024 ·Stroke and Vascular Neurology ·(unknown), Jichang Luo, Xuesong Bai, Eyad Almallouhi, Peng Gao, Delin Liu, Ran Xu, Wenlong Xu, (unknown), (unknown), Xiao Zhang, Taoyuan Lu, Jie Wang, Renjie Yang, (unknown), (unknown), (unknown), Colin P. Derdeyn, Liqun Jiao, Tao Wang	1
5	High-dose oxaliplatin induces severe hypersensitivity reactions and high recurrence rates during rechallenge in patients treated with hepatic arterial infusion chemotherapy 2024 ·International Immunopharmacology ·(unknown), (unknown), (unknown), (unknown), (unknown), Xin Zhang, (unknown), Xiaodong Wang, Guang Cao, (unknown), Hui Chen, Peng Liu, Haifeng Xu, (unknown), Renjie Yang, Xu Zhu	1
6	Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma 2024 ·Journal of Hepatocellular Carcinoma ·(unknown), (unknown), (unknown), (unknown), (unknown), Xin Zhang, (unknown), Xiaodong Wang, (unknown), Hui Chen, Peng Liu, Haifeng Xu, (unknown), Renjie Yang, (unknown), Xu Zhu	3
7	A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy 2023 ·Translational Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Xin Zhang, Xiaodong Wang, Guang Cao, Hui Chen, (unknown), Haifeng Xu, (unknown), Renjie Yang, Xu Zhu	8
8	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial breakdown → 2022 ·Radiology ·(unknown), Xu Zhu, (unknown), Guang Cao, Wenqing Li, Liang Xu, Hui Chen, Di Wu, Renjie Yang, Kun Wang, Wei Liu, Hongwei Wang, Quan Bao, Ming Liu, Chunyi Hao, Lin Shen, Baocai Xing, Xiaodong Wang	101
9	MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs 2021 ·International Journal of Biological Sciences ·Renjie Yang, (unknown), Shen Han, (unknown), (unknown), (unknown), (unknown), Yun Gao, (unknown), Yue Yu, Xuehao Wang	18
10	Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score‐Matched Analysis 2021 ·BioMed Research International ·(unknown), (unknown), Xu Zhu, (unknown), (unknown), (unknown), Xin Zhang, Xiaodong Wang, Guang Cao, Hui Chen, Peng Liu, (unknown), Haifeng Xu, Renjie Yang	20
11	Retrograde embolization technique of the right gastric artery during the implantation of port-catheter system for hepatic arterial infusion chemotherapy 2020 ·SHILAP Revista de lepidopterología ·(unknown), Guang Cao, Liang Xu, (unknown), Xu Zhu, Renjie Yang, Xiao Wang, Xiaodong Wang, (unknown), (unknown)	3
12	984P Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Vp3/4): A randomized phase II trial 2020 ·Annals of Oncology ·X. Wang, (unknown), Guang Cao, Liang Xu, Xu Zhu, (unknown), Shuai Fu, Di Wu, Renjie Yang, (unknown), (unknown), (unknown), (unknown), (unknown), Baocai Xing	1
13	Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma 2020 ·World Journal of Gastrointestinal Oncology ·(unknown), (unknown), Xu Zhu, (unknown), Xin Zhang, Hui Chen, Xiaodong Wang, Renjie Yang	16
14	Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer 2020 ·CardioVascular and Interventional Radiology ·(unknown), Xiaodong Wang, Guang Cao, Liang Xu, Xu Zhu, (unknown), (unknown), (unknown), Renjie Yang	6
15	Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma 2020 ·World Journal of Gastroenterology ·(unknown), (unknown), (unknown), (unknown), Xin Zhang, Di Wu, Xiaoting Li, Hui Chen, Xiaodong Wang, Peng Liu, Pengjun Zhang, Haifeng Xu, Guang Cao, (unknown), Renjie Yang, Xu Zhu	11
16	Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma 2017 ·Oncotarget ·Sheng Han, Dong Wang, Guohua Tang, (unknown), Chenyu Jiao, Renjie Yang, Yaodong Zhang, (unknown), (unknown), (unknown), Jiawei Zhang, (unknown)	16
17	Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27 2016 ·Journal of Experimental & Clinical Cancer Research ·Dong Wang, Sheng Han, Rui Peng, Chenyu Jiao, Xing Wang, (unknown), Renjie Yang, (unknown)	60
18	Transarterial chemoembolization as an adjuvant therapy in patients with hepatocellular carcinoma treated with hepatectomy 2010 ·Zhonghua fangshexian yixue zazhi ·(unknown), Jiaxing Zhang, Ying-Sheng Cheng, Renjie Yang, (unknown)	3
19	Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models 2009 ·Acta Pharmacologica Sinica ·(unknown), Yin Xu, Renjie Yang, Bin Wu, (unknown), Yide Qin, Qunwei Zhang	22
20	Progenitor geneDLK1might be an independent prognostic factor of liver cancer 2008 ·Expert Opinion on Biological Therapy ·(unknown), Renjie Yang, Bin Dong, Baocai Xing	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact